Director/PDMR Shareholding

RNS Number : 2073Z

Proteome Sciences PLC

10 January 2011

 



Proteome Sciences plc

Directorate Change

10 January, 2011 - Proteome Sciences plc (AIM:PRM), a leading provider of protein biomarker discovery, validation, and assay development services, announces that, further to the announcement made on 22 December 2010, Professor Alf Lindberg has today formally resigned from the board.

- Ends -

For further information please contact:

Proteome Sciences plc

www.proteomics.com                                              Tel:    [phone]

Christopher Pearce, Chief Executive Officer             [e-mail] 

James Malthouse, Finance Director                          [e-mail] 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: [phone]

Public Relations

IKON Associates                                                    Redleaf Communications Limited

Adrian Shaw                                                              Anna Dunkin/Lucy Salaman

Tel:          [phone]                                     Tel:        [phone]

Mobile:    [phone]                                     Email:     [e-mail] 

Email:      [e-mail]                                          

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications. These biomarkers are available for outlicensing. The first blood test for lung cancer using Proteome Sciences' biomarkers was launched in the USA in 2009 and received Medicare reimbursement in 2010. Its PS Biomarker Services provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany, using proprietary isobaric and isotopic Tandem Mass Tags^® (TMT^®) to discover protein biomarkers, and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in validation studies. Assays for validated biomarkers can be transferred for immunoassay development. Proteome Sciences, based in Cobham, UK, has facilities in London and Frankfurt and delivers outsourced proteomics services and proprietary biomarkers to pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.

 

END

 

 

RDSSFWFISFFSEDF